Literature DB >> 7439477

Contact allergy as a therapeutic tool for alopecia areata: application of squaric acid dibutylester.

R Happle, K J Kalveram, U Büchner, K Echternacht-Happle, W Göggelmann, K H Summer.   

Abstract

Squaric acid dibutylester (SADBE), a potent contact allergen, was tested for mutagenicity in the bacterial plate incorporation assay (Ames test), in the presence and absence of mammalian microsomes. In contrast to dinitrochlorobenzene which is mutagenic in this test, SADBE was found not to be mutagenic. In 53 patients with extensive or total alopecia areata, SADBE dissolved in acetone was applied weekly to one side of the head, the other side serving as control. In 46 patients (87%), hair regrew either exclusively on the treated side, or considerably faster and denser on this side. In some patients, continuous treatment failed to maintain the response. Persistent response was observed in 37 patients (70%). These results are essentially the same as those obtained with DNCB. Therefore, contact allergy is proposed as a therapeutic concept for alopecia areata.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7439477     DOI: 10.1159/000250380

Source DB:  PubMed          Journal:  Dermatologica        ISSN: 0011-9075


  9 in total

1.  Topical immunotherapy with contact allergens in alopecia areata: evidence for non-specific systemic suppression of cellular immune reactions.

Authors:  E B Bröcker; S M John; D Steinhausen; H Hamm
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

Review 2.  The role of lymphocytes in the development and treatment of alopecia areata.

Authors:  Hongwei Guo; Yabin Cheng; Jerry Shapiro; Kevin McElwee
Journal:  Expert Rev Clin Immunol       Date:  2015-09-07       Impact factor: 4.473

Review 3.  Alopecia Areata: a Comprehensive Review of Pathogenesis and Management.

Authors:  Ralph M Trüeb; Maria Fernanda Reis Gavazzoni Dias
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

4.  Percutaneous penetration of squaric acid and its esters in hairless mouse and human skin in vitro.

Authors:  E F Sherertz; K B Sloan
Journal:  Arch Dermatol Res       Date:  1988       Impact factor: 3.017

5.  Topical therapy for regression and melanoma prevention of congenital giant nevi.

Authors:  Yeon Sook Choi; Tal H Erlich; Max von Franque; Inbal Rachmin; Jessica L Flesher; Erik B Schiferle; Yi Zhang; Marcello Pereira da Silva; Alva Jiang; Allison S Dobry; Mack Su; Sharon Germana; Sebastian Lacher; Orly Freund; Ezra Feder; Jose L Cortez; Suyeon Ryu; Tamar Babila Propp; Yedidyah Leo Samuels; Labib R Zakka; Marjan Azin; Christin E Burd; Norman E Sharpless; X Shirley Liu; Clifford Meyer; William Gerald Austen; Branko Bojovic; Curtis L Cetrulo; Martin C Mihm; Dave S Hoon; Shadmehr Demehri; Elena B Hawryluk; David E Fisher
Journal:  Cell       Date:  2022-05-12       Impact factor: 66.850

6.  Chronic delayed-type hypersensitivity reaction as a means to treat alopecia areata.

Authors:  M Zöller; P Freyschmidt-Paul; M Vitacolonna; K J McElwee; S Hummel; R Hoffmann
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

7.  Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population.

Authors:  Shahin Aghaei
Journal:  BMC Dermatol       Date:  2005-05-26

Review 8.  Application of Topical Immunotherapy in the Treatment of Alopecia Areata: A Review and Update.

Authors:  Thipprapai Mahasaksiri; Chaninan Kositkuljorn; Tanaporn Anuntrangsee; Poonkiat Suchonwanit
Journal:  Drug Des Devel Ther       Date:  2021-03-23       Impact factor: 4.162

9.  Comparative Study of Efficacy and Safety of Topical Squaric Acid Dibutylester and Diphenylcyclopropenone for the Treatment of Alopecia Areata.

Authors:  Anup K Tiwary; Dharmendra K Mishra; S S Chaudhary
Journal:  N Am J Med Sci       Date:  2016-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.